Table 3 Outcomes before and after intravenous immunoglobulin treatment of patients with postpolio syndrome

Bertolasi [2013] [14]

SF-36, 6MWT, muscle strength, FSS, and VAS at 2 and 4 mo

Significant improvements in RP, mental component score, and RE of the SF-36 at 2 mo.

Farbu [2007] [12]

VAS, muscle strength, and FSS at 1, 3, and 6 mo; TNF-α, IFN-γ, IL-6, IL-1β, IFN-β, and IL-10 levels in CSF and serum measured using enzyme-linked immunosorbent assay at 1 mo

Significant alleviation of in pain at 3 mo; significantly decreased CSF TNF-α levels (P = 0.028; no significant differences after regression because of the differences in the baseline values).

Gonzalez [2006] [10]

SF-36, VAS, MFI-20, PASE, 6MWT, TUG, muscle strength, balance, and sleep quality at 9–13 wk

Significant improvements in the strength of the affected muscles and the vitality scores of the SF-36 and PASE.

Gonzalez [2012] [5]

SF-36, 6MWT, and VAS; IFN-γ, TNF, IL-10, IL-13, IL-23, and TGF-β levels in PBMCs and CSF at 1 year

Significant improvements in the physical components of the SF-36, VAS scores, and 6MWT. Significant decrease in the CSF IFN-γ and IL-23 levels but significant increase in the CSF IL-13 levels.

Gonzalez [2004] [13]

IFN-γ, TNF-α, IL-10, and IL-4 levels in PBMCs and CSF at 6–8 wk

Significant decrease in the CSF IFN-γ and TNF-α mRNA levels and significant increase in the PBMCs IL-4 levels.

Kaponides [2006] [8]

SF-36 at 2 and 6 mo; 6MWT and muscle strength at 2 mo

Significant improvements in the PF, RP, BP, GH, VT, SF, and MH subdomains of the SF-36 at 2 and 6 mo.

Östlund [2012] [11]

SF-36, PASE, and VAS at 6 mo

Significant improvement of pain in patients with VAS score > 2 cm, age < 65 y, and paresis of the lower limbs. Significant improvements in the BP, VT, SF, RE subdomains of the SF-36.

Werhagen[2011] [9]

VAS at 6 mo

31/45 (69%) patients exhibited significant improvements in the mean VAS scores, which decreased from 53 to 42 (p = 0.001).